The following content is a sponsored message. It is provided by the advertiser and does not reflect the views, research, or recommendations of Moby. Please do your own research before making any investment decisions.

BREAKING NEWS

Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) has picked up a new lab partner that doesn't need goggles, gloves, or a bigger budget. The company announced it has completed its acquisition of Molecule.ai, an artificial intelligence platform built for molecular discovery and drug development. In practical terms, Shuttle just plugged machine learning, predictive analytics, and data science directly into its oncology R&D engine.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

For the uninitiated, Shuttle is a clinical-stage biotech with a focused goal: make radiation therapy work better and hurt less. Its lead candidate, Ropidoxuridine, is in Phase II trials and is designed to sensitize tumors to radiation while limiting damage to healthy tissue. That promise sits at the center of the radiotherapy wish list and explains why investors put up with long timelines and regulatory limbo. Molecule.ai is meant to speed things up. The platform helps researchers move faster on compound selection, modeling, and early decision-making, where delays and bad calls tend to get expensive.

Shuttle is bettingthat tighter feedback loops mean fewer wasted cycles. The deal also lands squarely in biotech's favorite narrative right now: AI as a cure for inefficient R&D. Sometimes that's just marketing. This one might actually earn the headline .

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.